Clinical next generation sequencing to identify actionable aberrations in a phase I program (Q36299589)

13 August 2017

Clinical next generation sequencing to identify actionable aberrations in a phase I program (English)

1 reference

13 August 2017

20

Funda Meric-Bernstam

1 reference

13 August 2017

10

Aung Naing

1 reference

13 August 2017

13

Filip Janku

1 reference

13 August 2017

19

Gordon B Mills

1 reference

13 August 2017

17

Kenna Shaw

1 reference

13 August 2017

Genevieve M Boland

1

1 reference

13 August 2017

Sarina A Piha-Paul

2

1 reference

13 August 2017

Vivek Subbiah

3

1 reference

13 August 2017

Mark Routbort

4

1 reference

13 August 2017

Shelley M Herbrich

5

1 reference

13 August 2017

Keith Baggerly

6

1 reference

13 August 2017

Keyur P Patel

7

1 reference

13 August 2017

Lauren Brusco

8

1 reference

13 August 2017

Chacha Horombe

9

1 reference

13 August 2017

Siqing Fu

11

1 reference

13 August 2017

David S Hong

12

1 reference

13 August 2017

Amber Johnson

14

1 reference

13 August 2017

Russell Broaddus

15

1 reference

13 August 2017

Raja Luthra

16

1 reference

13 August 2017

John Mendelsohn

18

1 reference

13 August 2017

language of work or name

English

0 references

publication date

8 May 2015

1 reference

13 August 2017

1 reference

13 August 2017

6

1 reference

13 August 2017

24

1 reference

13 August 2017

20099-20110

1 reference

A decision support framework for genomically informed investigational cancer therapy

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4652990

Acquired resistance to TKIs in solid tumours: learning from lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4652990

Oncogenic KRAS signalling in pancreatic cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4652990

Concordance of genomic alterations between primary and recurrent breast cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4652990

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4652990

Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4652990

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4652990

Targeting MEK for the treatment of non-small-cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4652990

Personalized oncology through integrative high-throughput sequencing: a pilot study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4652990

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4652990

International network of cancer genome projects

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4652990

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4652990

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4652990

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4652990

The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4652990

P53 abnormalities and outcomes in colorectal cancer: a systematic review.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4652990

Clinical actionability enhanced through deep targeted sequencing of solid tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4652990

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4652990

Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4652990

FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4652990

Is there a role for routine p53 testing in colorectal cancer?

22 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26015395

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.18632/ONCOTARGET.4040

0 references

1 reference

13 August 2017

1 reference